Diagnostic e prognostic markers applicable for clinical pratic for patients with thyroid nodules: validation of imunoexpression of proteins HMGA2,LAMB3,CLDN10

• Grant number: 18/26126-4
• Support type: Regular Research Grants
• Duration: May 01, 2019 - April 30, 2021
• Field of knowledge: Health Sciences - Medicine - Pathological Anatomy and Clinical Pathology
• Principal researcher: Maria Aparecida Custódio Domingues
• Grantee: Maria Aparecida Custódio Domingues
• Home Institution: Faculdade de Medicina (FMB). Universidade Estadual Paulista (UNESP). Campus de Botucatu. Botucatu , SP, Brazil
• Assoc. researchers: Flávia Fazzio Barbin

Abstract

Thyroid cancer (TC) is the most common cancer of head and neck topography. TC may be suspected starting from a thyroid nodule palpation during physical examination, which leads to thyroid ultrasound request. Fine needle aspiration (FNA) associated to this imagem exam is the gold standard for the preoperative thyroid cancer diagnosis. The cytopathological findings in thyroid FNAs are classified in six categories (from I to VI) acording to The Bethesda System for Reporting Thyroid Cytopathology (SB), 2017, which also specifies the recommended management for each of them. Cases diagnosed as category III, IV or V are frequently managed with total thyroidectomy, even though in many cases the corresponding histopathological findings are consistent with benign lesions. Molecular researchs have being looking for markers that differentiate between benignity and malignancy, over all in cases classified as category III, IV and V, and using thyroid FNA materials. These markers have not been found found up to this moment. It is then essential that there are markers capable of distinguish between these lesions. Previous studies have demonstratedthat HMGA2,CLDN10 AND LAMB3 genes show high specificity and sensibility in this differentiation. This study aims to: (1) validate the application of these markers (using immunohistochemistry - IHC) in thyroid FNAs cell-blocks reviewd and classified as category II, IV or V according to BS, (2) correlate these findings to the histopathological ones of the corresponding surgical specimen and to the prognostic of the patients studied. To this end, there will be reviewed retrospectively, one hundred thyroid nodules FNAs, classified according to SB, 2017. Clinical informations will be colected as well as the anatomopathologic reports of the corresponding surgical specimens. The cell-blocks will be submitted to immunohistochemistry study for the proteins encoded by the genes (determined in previous studies) in the samples diagnosed as categories III, IV or V.It is expected to validate these proteins as potential markers of malignancy and study their prognostic potential. (AU)